Neuraxpharm
Neuraxpharm, a leading pharmaceutical company headquartered in Spain, is renowned for its commitment to improving the lives of patients with central nervous system (CNS) disorders. Founded in 1985, the company has established a strong presence across Europe, focusing on the development and distribution of innovative treatments for mental health conditions, including depression and anxiety. With a diverse portfolio of products, Neuraxpharm stands out for its specialised formulations and patient-centric approach. The company has achieved significant milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical industry, Neuraxpharm continues to prioritise research and development, solidifying its position as a key player in the CNS market.
DitchCarbon Score
How does Neuraxpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neuraxpharm's score of 31 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neuraxpharm's reported carbon emissions
In 2023, Neuraxpharm reported total carbon emissions of approximately 117,214,000 kg CO2e. This figure includes 1,655,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 1,757,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The majority of their emissions, about 113,801,000 kg CO2e, fall under Scope 3, which encompasses all other indirect emissions that occur in the value chain. Comparatively, in 2022, Neuraxpharm's total emissions were significantly lower at approximately 3,526,000 kg CO2e, with Scope 1 emissions at 2,064,000 kg CO2e and Scope 2 emissions at 1,462,000 kg CO2e. The data from previous years shows a consistent increase in emissions, particularly in Scope 3, which indicates a growing impact from their supply chain and product use. Neuraxpharm has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi) or similar climate pledges. The absence of documented reduction targets suggests a need for further development in their sustainability strategy. This emissions data is not cascaded from any parent organization, indicating that Neuraxpharm's reporting is independent. The company is headquartered in Spain (ES) and is focused on addressing its carbon footprint as part of its broader environmental, social, and governance (ESG) commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 658,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,038,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neuraxpharm is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
